United States Patent 9,629,797: Carbamazepine Intravenous Replacement Therapy Patent Scope and Landscape
US 9,629,797 protects therapeutic administration of an intravenous carbamazepine formulation complexed with a sulfoalkyl-cyclodextrin, principally sulfobutylether-7-beta-cyclodextrin, as a temporary substitute for oral carbamazepine. The commercial embodiment is consistent with Carnexiv, an intravenous carbamazepine product containing 10 mg/mL carbamazepine and 25% w/v sulfobutylether-beta-cyclodextrin.
The patent does not broadly claim carbamazepine, cyclodextrin, or the formulation as a composition of matter. Its claims are method-of-treatment claims. Infringement generally requires performance of the claimed administration method, including the specified patient population, route, dose conversion, formulation concentration, infusion period, and pharmacokinetic result where applicable.
The commercially important claims are 25 through 35 and 44 through 57. They combine the formulation, intravenous route, replacement of oral therapy, a 65% to 75% oral-dose conversion, and therapeutic exposure criteria. The patent therefore presents its greatest risk to an intravenous carbamazepine product used according to the Carnexiv dosing protocol rather than to an unrelated carbamazepine formulation or oral generic.
What does US 9,629,797 claim?
The patent has four principal claim groups.
| Claim group |
Core scope |
Commercial significance |
| Claims 1-16 |
Parenteral administration of carbamazepine in a sulfoalkyl-cyclodextrin composition at 30% to 100% of the oral maintenance dose |
Broadest claim set, but includes multiple noncommercial routes |
| Claims 17-24 |
Intravenous administration to a patient with a seizure disorder at 30% to 100% of the oral dose |
Covers the central clinical use but remains broader than the approved dosing protocol |
| Claims 25-35 |
Specific 10 mg/mL carbamazepine and 25% w/v cyclodextrin formulation, intravenous administration, 65% to 75% dose conversion, and 5- to 60-minute infusion |
Strongest direct overlap with the commercial product |
| Claims 36-43 |
Specific formulation and intravenous use with dose conversion, AUC, trough, and minimum-concentration limitations |
Narrower pharmacokinetic claims |
| Claims 44-57 |
Specific seizure types, formulation, intravenous route, 65% to 75% dose conversion, and 5- to 60-minute infusion |
Narrow commercial-use claims directed to conventional epilepsy indications |
The independent claims are claims 1, 17, 25, 36, and 44. The remaining claims add narrower limitations concerning concentration, cyclodextrin identity, seizure type, infusion duration, dosing interval, dose conversion, and pharmacokinetic performance.
How broad is claim 1?
Claim 1 requires all of the following:
- A human patient in need of treatment.
- A carbamazepine sulfoalkyl-cyclodextrin composition.
- Parenteral infusion.
- Use as a replacement for oral carbamazepine.
- Administration at approximately 30% to 100% of the patient's oral maintenance dose.
Claim 1 is broader than the later claims in several respects. It does not require:
- Intravenous administration specifically;
- A seizure disorder;
- Sulfobutylether-7-beta-cyclodextrin;
- A 10 mg/mL carbamazepine concentration;
- A 25% w/v cyclodextrin concentration;
- A 65% to 75% dose conversion;
- A defined infusion time;
- A particular AUC or trough concentration.
The term "parenterally infusing" should be read in the context of the dependent claims, which identify intravenous, intraarterial, intramuscular, subcutaneous, and intraperitoneal administration. Claim 1 therefore has potentially broad route coverage, although its practical value is concentrated in intravenous treatment.
A product used solely as a new initial therapy, rather than as a replacement for oral carbamazepine, would present a stronger noninfringement position against claim 1. The replacement limitation is material.
What formulation is protected by US 9,629,797?
The most specific formulation limitations appear in claims 25, 36, and 44:
- Carbamazepine: approximately 10 mg/mL;
- Sulfobutylether-7-beta-cyclodextrin: approximately 25% w/v;
- Intravenous administration;
- Replacement for oral carbamazepine;
- Dose generally equal to 65% to 75% of the oral daily dose.
The patent claims the formulation only as an element of a treatment method. It does not, based on the claims supplied, independently claim a vial, prefilled syringe, bulk solution, pharmaceutical composition, or manufacturing process containing those ingredients.
That distinction matters for generic strategy. Making or possessing a formulation with the same concentrations is not necessarily enough to infringe the asserted method claims. Liability becomes more likely when the product labeling, prescribing information, promotional materials, dosing instructions, or institutional-use protocols direct the patented intravenous replacement regimen.
What is the commercial product associated with the patent?
The claimed formulation corresponds closely to Carnexiv, an intravenous carbamazepine product developed for temporary replacement of oral carbamazepine when oral administration is not feasible. The FDA-approved product contains 10 mg/mL carbamazepine in a sulfobutylether-beta-cyclodextrin vehicle and is administered intravenously as a replacement regimen.
The FDA labeling identifies a dose conversion based on the patient's total daily oral carbamazepine dose. The labeled intravenous daily dose is generally 70% of the oral daily dose, divided into four equal infusions administered at six-hour intervals. Each infusion is administered over approximately 30 minutes.[2]
That regimen falls within the limitations of claims 25, 26, 29, and 30:
- 65% to 75% of the oral daily dosage;
- Approximately 70% of the oral daily dosage;
- Administration over approximately 30 minutes;
- Dosing every four to 12 hours.
The approved indication is temporary replacement therapy in patients with epilepsy when oral administration is temporarily not feasible. The label does not establish the same commercial significance for status epilepticus that the patent claims recite.[2]
Which claims are most important for patent enforcement?
Claims 25 and 44
Claims 25 and 44 are the closest to a conventional commercial infringement case. They require:
- A patient with epilepsy, status epilepticus, or specified seizure types;
- Carbamazepine at approximately 10 mg/mL;
- Sulfobutylether-7-beta-cyclodextrin at approximately 25% w/v;
- Intravenous administration;
- Replacement of oral carbamazepine;
- A daily dose equal to approximately 65% to 75% of the oral dose;
- An infusion period of approximately five to 60 minutes.
A product used according to the FDA-approved Carnexiv protocol would likely satisfy most, and potentially all, of these limitations.
Claims 36 and 44-57
These claims add pharmacokinetic limitations. They require the AUC and minimum plasma concentration to fall within specified percentages of the corresponding oral-maintenance-dose values. Claims 36 through 43 use a 70% to 130% range. Claims 13, 14, 15, 16, and the later dependent claims also recite narrower or alternative 80% to 125% ranges.
These limitations create two opposing effects:
- They provide a narrower claim that may be harder to invalidate based on broad prior art.
- They create proof issues because infringement may require patient-specific pharmacokinetic data, validated testing, or an inference from the product's approved dosing protocol.
A generic or alternative product could attempt to avoid these claims through a materially different dose conversion or exposure profile. That strategy would not necessarily avoid claims 25 or 44 if the product still uses the specified formulation, route, clinical population, dose range, and infusion time.
Claims 17-24
Claims 17 through 24 are broader in formulation and dosing terms than claims 25 and 44. They cover intravenous use in a patient with a seizure disorder at 30% to 100% of the oral dose. They do not require the specific 10 mg/mL and 25% w/v formulation.
These claims may be more vulnerable to prior-art challenges involving earlier intravenous carbamazepine formulations or dose-conversion studies. Their broader scope also gives them greater potential relevance against non-Carnexiv formulations.
What seizure disorders are covered?
The patent expressly identifies:
- Partial seizures with complex symptoms;
- Generalized tonic-clonic seizures;
- Mixed seizure patterns;
- Epilepsy;
- Status epilepticus;
- Refractory seizure disorders.
Claims 6 through 9, 20 through 24, and 37 through 47 divide these conditions into dependent claim categories. Claims 44 through 57 focus on partial seizures with complex symptoms, generalized tonic-clonic seizures, and mixed seizure patterns.
The seizure-type limitations narrow the claims but also create potential claim-construction disputes. For example, a patient with a seizure disorder that does not fall within the specified diagnostic categories may not satisfy claims limited to those categories. Claims directed generally to "a seizure disorder," however, remain broader.
The patent's use of "status epilipticus" appears to be a typographical error for "status epilepticus." The intended clinical condition is apparent, but the error could create an interpretation issue if the term is disputed in litigation.
What is the difference between the broad and narrow dose claims?
The patent establishes three dose-conversion tiers.
| Dose limitation |
Claims using the limitation |
Effect |
| 30% to 100% of oral maintenance dose |
Claims 1 and 17, with dependents |
Broad dose range |
| 65% to 75% of oral daily dose |
Claims 3, 25, 36, and 44, with dependents |
Core commercial range |
| Approximately 70% of oral daily dose |
Claims 30 and 52 |
Narrower preferred embodiment |
A product administered at 70% of the patient's oral daily dose is within all three ranges. A product administered at 50% is within the 30% to 100% range but outside the 65% to 75% range. A product administered at 80% is within the 30% to 100% range but outside the 65% to 75% and approximately 70% limitations.
The use of "about" introduces a potential numerical-equivalence issue. The scope of "about 70%" would depend on intrinsic evidence, prosecution history, technical meaning, and the actual dosing protocol.
What infusion times are protected?
Claims 25 and 44 cover an infusion period of approximately five to 60 minutes. Dependent claims identify:
- Approximately 30 minutes;
- Approximately 15 minutes;
- Approximately five minutes.
The 30-minute administration time is the principal commercial embodiment. A five-minute infusion may implicate claims 28 and 50. A 15-minute infusion may implicate claims 27 and 49. A 60-minute infusion may remain within the parent claim if it satisfies the "about five to about 60 minutes" limitation.
An infusion materially longer than 60 minutes could avoid these narrow claims, but it may remain within broader claims that do not specify a time period.
Does the patent claim manufacturing or supply of the formulation?
No independent claim supplied here directly claims:
- Manufacturing sulfobutylether-7-beta-cyclodextrin;
- Manufacturing carbamazepine;
- Preparing the 10 mg/mL solution;
- Filling a vial;
- Packaging;
- Sterilization;
- Quality-control testing;
- The cyclodextrin excipient as a standalone product.
The patent is principally a use patent. Manufacturing and formulation risk must therefore be evaluated against separate composition, excipient, process, and container-closure patents, if any. Those rights are distinct from the treatment claims in US 9,629,797.
How strong is the patent estate?
The patent has moderate commercial strength and uneven legal breadth.
Strengths
- The narrow claims closely track the approved intravenous replacement regimen.
- The formulation, route, dose conversion, and infusion time are recited together.
- Claims 25 and 44 create direct overlap with a product administered according to the labeled protocol.
- The claims cover both general seizure-disorder treatment and specified seizure types.
- Pharmacokinetic claims provide additional fallback positions.
Weaknesses
- The patent does not claim the composition independently.
- Broad claims may face prior art involving carbamazepine cyclodextrin formulations, parenteral administration, and oral-to-intravenous dose conversion.
- "About" ranges may create numerical-boundary disputes.
- "Replacement for oral carbamazepine" can be difficult to prove where the product is used under a broad hospital protocol.
- AUC, trough, and minimum-concentration limitations may require patient-specific evidence.
- Several claims are highly overlapping and may provide limited additional scope beyond the commercial core.
The best enforcement theory would generally focus on claims 25 or 44 against a labeled intravenous product that reproduces the Carnexiv formulation and dosing instructions.
What generic entry risks exist?
ANDA pathway
A conventional ANDA applicant would need to address listed patents and labeling requirements for the reference product. A Paragraph IV certification could challenge the patent before expiration. If the applicant uses a label directing intravenous replacement therapy at approximately 70% of the oral dose, the risk of infringement allegations would be highest under claims 25 and 44.
A label carve-out could be difficult if the patented use is coextensive with the product's principal FDA-approved use. The relevant question would be whether the proposed labeling can omit the patented method while retaining an approvable, noninfringing use.
505(b)(2) pathway
A reformulated or differently dosed intravenous carbamazepine product could use the 505(b)(2) pathway. Potential design-around variables include:
- A different cyclodextrin or solubilizing system;
- A carbamazepine concentration outside the claimed approximately 10 mg/mL range;
- A dose conversion outside 65% to 75%;
- A materially different infusion period;
- A use limited to initial therapy rather than replacement of oral therapy;
- A different indication or patient population.
These changes may avoid some narrow claims while leaving broader claims 1 or 17 in issue.
Biosimilar risk
There is no biosimilar pathway for carbamazepine. Carbamazepine is a small-molecule active pharmaceutical ingredient. Competitive entry would proceed through an ANDA, 505(b)(2) application, or an independent full NDA, not through the Biologics Price Competition and Innovation Act pathway.
What is the Orange Book and FDA status?
Carnexiv was approved by FDA as an intravenous carbamazepine product for temporary replacement of oral therapy when oral administration was not feasible.[2] FDA's Orange Book is the controlling source for current patent listings, use codes, product status, and any applicable exclusivity information.[1]
US 9,629,797 should be evaluated as a listed-drug patent only in relation to the specific reference product and the Orange Book entry applicable to that product. The existence of the patent alone does not establish that every claim remains listed, enforceable, or blocking. Listing status, patent-term adjustment, terminal disclaimers, maintenance fees, disclaimers, and post-grant proceedings must be checked against the current USPTO and FDA records.
The patent is a small-molecule use patent, not a biologic exclusivity right. FDA approval exclusivity and patent exclusivity are separate. Approval of a generic or 505(b)(2) product depends on FDA requirements, while patent-based entry depends on certification, litigation, settlement, and any applicable statutory stay.
What litigation or Paragraph IV activity affects the patent?
The claims supplied do not identify any litigation, Paragraph IV certification, settlement agreement, license, or covenant not to sue. No litigation conclusion can be drawn from the claim text alone.
For commercial diligence, the relevant records are:
- FDA Orange Book patent listings;
- FDA Paragraph IV notification records;
- PACER filings involving the patent number or Carnexiv;
- USPTO assignment and maintenance-fee records;
- PTAB proceedings;
- Any Hatch-Waxman settlement filed under FDA reporting requirements.
A Paragraph IV challenge would likely target one or more of the following issues:
- Obviousness based on known intravenous carbamazepine formulations and oral-to-parenteral dose conversion.
- Written description or enablement for the full dose and pharmacokinetic ranges.
- Indefiniteness of "about," "therapeutic range," or "oral maintenance dose."
- Anticipation by prior clinical or formulation disclosures.
- Noninfringement based on a different cyclodextrin, concentration, dose, route, indication, or infusion protocol.
How does US 9,629,797 compare with composition patents?
US 9,629,797 is narrower in subject matter but potentially more relevant to a marketed intravenous product than an expired or nonblocking composition patent.
| Patent category |
Typical protected subject matter |
Relevance to Carnexiv-type entry |
| Active-ingredient patent |
Carbamazepine molecule or salt |
Likely limited if expired |
| Cyclodextrin patent |
Sulfoalkyl-cyclodextrin or Captisol-type excipient |
Manufacturing and formulation relevance |
| Composition patent |
Specific carbamazepine-cyclodextrin solution |
Direct product relevance |
| Method-of-treatment patent |
Intravenous replacement dosing |
Direct label and use relevance |
| Manufacturing patent |
Preparation, sterilization, filling, or process controls |
Supply-chain relevance |
| Regulatory exclusivity |
FDA approval-based exclusivity |
Separate from patent rights |
The principal freedom-to-operate issue is therefore cumulative. Avoiding US 9,629,797 may not eliminate risk under formulation, process, excipient, or regulatory rights.
Key Takeaways
- US 9,629,797 is a method-of-treatment patent covering parenteral, particularly intravenous, administration of carbamazepine in a sulfoalkyl-cyclodextrin formulation.
- Its strongest commercial claims require approximately 10 mg/mL carbamazepine, 25% w/v sulfobutylether-7-beta-cyclodextrin, a 65% to 75% oral-dose replacement, and a five- to 60-minute infusion.
- The 70% oral-dose, four-times-daily, 30-minute infusion protocol closely corresponds to the Carnexiv labeling.
- The patent does not independently claim the formulation or its manufacture based on the claims supplied.
- A generic or 505(b)(2) applicant could pursue design-around strategies involving formulation, dose conversion, infusion time, indication, or replacement-use labeling.
- Carbamazepine has no biosimilar pathway. Entry would proceed through an ANDA, 505(b)(2) application, or full NDA.
- Paragraph IV risk is concentrated in claims 25 and 44, with broader fallback exposure under claims 1 and 17.
- Current Orange Book listing, patent-term data, litigation, and settlement status must be confirmed from FDA, USPTO, PTAB, and PACER records.
FAQs About US 9,629,797
Does US 9,629,797 cover oral carbamazepine?
No. The claims require parenteral administration and are directed to intravenous or other nonoral replacement therapy.
Does changing the cyclodextrin avoid the patent?
It may avoid claims specifically requiring sulfobutylether-7-beta-cyclodextrin, but broader claims referring to a sulfoalkyl-cyclodextrin may remain relevant.
Is a 70% intravenous dose within the patent claims?
Yes. A 70% replacement dose falls within both the broad 30% to 100% range and the narrower 65% to 75% range.
Can a product avoid the patent by using a 60-minute infusion?
Not necessarily. Claims 25 and 44 expressly cover an infusion period of approximately five to 60 minutes. A longer infusion may avoid those claims but could remain subject to broader claims.
Does a different carbamazepine concentration eliminate infringement risk?
It may avoid claims requiring approximately 10 mg/mL, but it would not automatically avoid broader claims that do not recite a concentration.
References
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2016). Carnexiv (carbamazepine) injection, for intravenous use: Prescribing information.
- United States Patent and Trademark Office. (2017). U.S. Patent No. 9,629,797, methods of administering carbamazepine.
- U.S. Food and Drug Administration. (n.d.). Approved drug products database and FDA drug approval records.
- U.S. Patent and Trademark Office. (n.d.). Patent Center and patent maintenance-fee records.
